Clinical Validation of MyProstateScore 2.0 - Testing Using First-Catch, Non-DRE Urine

Sep 23, 2026

Uploaded by Margaret

Purpose: Validate the 18-gene MyProstateScore 2.0 (MPS2) test for detecting Grade Group ≥2 prostate cancer using first-catch, non-digital rectal examination (DRE) urine, improving testing convenience beyond prior post-DRE urine validation. Materials and Methods: Patients provided first-catch urine before biopsy; MPS2 values were computed with models using biomarkers alone, biomarkers plus clinical factors, and biomarkers plus clinical factors plus prostate volume. Primary outcome was biopsy-confirmed GG ≥2 cancer, with performance and clinical consequences compared with PSA and the PCPTrc risk calculator.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages16

Reading Time40 min

AccessFree to download

Abstract

Purpose

Materials and Methods

Results

Author Manuscript Author Manuscript Author Manuscript Author Manuscript | | HHS Public Access
Author manuscript
J Urol. Author manuscript; available in PMC 2025 May 14. | | --- | --- | Published in final edited form as: J Urol. 2025 May ; 213(5): 581–589. doi:10.1097/JU.0000000000004421 . Clinical Validation of MyProstateScore 2.0 Testing Using FirstCatch, Non-DRE Urine Jeffrey J. Tosoian 1,2 , Yuping Zhang3 , Jacob I. Meyers4 , Spencer Heaton4 , Javed Siddiqui3 , Lanbo Xiao3 , Keavash D. Assani 1 , Daniel A. Barocas 1,2 , Ashley E. Ross5 , This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. Corresponding Author Information: Jeffrey J. Tosoian, MD, MPH, Department of Urology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, A-1302 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2765, Fax: 615-322-8990, [jeff.tosoian@vumc.org](jeff.tosoian@vumc.org). | Author | Email | Affiliation | | --- | --- | --- | | Jeffrey J. Tosoian | [jeff.tosoian@vumc.org](jeff.tosoian@vumc.org) | Department of Urology, Vanderbilt University Medical Center; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee | | Yuping Zhang | [yupingz@med.umich.edu](yupingz@med.umich.edu) | Department of Pathology, University of Michigan, Ann Arbor, MI | | Jacob I. Meyers | [jacob.meyers@Lynxdx.com](jacob.meyers@Lynxdx.com) | Lynx Dx, Ann Arbor, MI | | Spencer Heaton | [spencer@Lynxdx.com](spencer@Lynxdx.com) | Lynx Dx, Ann Arbor, MI | | Javed Siddiqui | [siddiqui@med.umich.edu](siddiqui@med.umich.edu) | Department of Pathology, University of Michigan, Ann Arbor, MI | | Lanbo Xiao | [lanbox@med.umich.edu](lanbox@med.umich.edu) | Department of Pathology, University of Michigan, Ann Arbor, MI | | Keavash D. Assani | [keavash.assani@vumc.org](keavash.assani@vumc.org) | Department of Urology, Vanderbilt University Medical Center; Nashville, Tennessee | | Daniel A. Barocas | [dan.barocas@vumc.org](dan.barocas@vumc.org) | Department of Urology, Vanderbilt University Medical Center; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee | | Ashley E. Ross | [ashley.ross@nm.org](ashley.ross@nm.org) | Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois | | Zoey Chopra | [zchopra@med.umich.edu](zchopra@med.umich.edu) | Department of Urology, University of Michigan, Ann Arbor, MI | | Grace C. Herron | [graherro@med.umich.edu](graherro@med.umich.edu) | Department of Urology, University of Michigan, Ann Arbor, MI | | Jacob A. Edelson | [jedels@med.umich.edu](jedels@med.umich.edu) | Department of Urology, University of Michigan, Ann Arbor, MI | | Nathan J. Graham | [Nathan.Graham@uchicagomedicine.org](Nathan.Graham@uchicagomedicine.org) | Department of Urology, University of Chicago Medicine, Chicago, IL | | Udit Singhal | [usinghal@med.umich.edu](usinghal@med.umich.edu) | Department of Urology, University of Michigan, Ann Arbor, MI Rogel Cancer Center, Ann Arbor, MI | | Simpa S. Salami | [simpa@med.umich.edu](simpa@med.umich.edu) | Department of Urology, University of Michigan, Ann Arbor, MI Rogel Cancer Center, Ann Arbor, MI | | Todd M. Morgan | [tomorgan@med.umich.edu](tomorgan@med.umich.edu) | Department of Urology, University of Michigan, Ann Arbor, MI Rogel Cancer Center, Ann Arbor, MI | | Ganesh S. Palapattu | [gpalapat@med.umich.edu](gpalapat@med.umich.edu) | Department of Urology, University of Michigan, Ann Arbor, MI Rogel Cancer Center, Ann Arbor, MI | | John T. Wei | [jtwei@med.umich.edu](jtwei@med.umich.edu) | Department of Urology, University of Michigan, Ann Arbor, MI Rogel Cancer Center, Ann Arbor, MI | | Arul M. Chinnaiyan | [arul@med.umich.edu](arul@med.umich.edu) | Department of Pathology, University of Michigan, Ann Arbor, MI; Department

FAQs

What is the purpose of validating MyProstateScore 2.0 in this study?

The study aims to validate the 18-gene MyProstateScore 2.0 (MPS2) test for detecting Grade Group ≥2 prostate cancer using first-catch, non-DRE urine, making testing easier than the prior post-DRE approach.

How were MPS2 values calculated in the Materials and Methods?

MPS2 values were calculated using models that differed only in included inputs: biomarkers alone (BA), biomarkers plus clinical factors (BA+CF), and biomarkers plus clinical factors plus prostate volume (BA+CF+PV).

What was the primary outcome and what comparisons were made?

The primary outcome was biopsy-confirmed GG ≥2 cancer. Test performance and clinical consequences were compared with PSA and the Prostate Cancer Prevention Trial risk calculator (PCPTrc).

Sep 23, 2026

Uploaded by Margaret